ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

ClinicalTrials.gov ID: NCT03610646

Public ClinicalTrials.gov record NCT03610646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

Study identification

NCT ID
NCT03610646
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Enrollment
355 participants

Conditions and interventions

Interventions

  • Eylea Drug
  • MYL-1701P Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 22, 2018
Primary completion
Nov 9, 2020
Completion
Sep 9, 2021
Last update posted
Mar 6, 2023

2018 – 2021

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
12
Facility City State ZIP Site status
Mylan Investigator Site Phoenix Arizona 85014
Mylan Investigator Site Phoenix Arizona 85020
Mylan Investigator Site Sacramento California 95841
Mylan Investigator Site St. Petersburg Florida 33711
Mylan Investigator Site Winter Haven Florida 33880
Mylan Investigator Site Augusta Georgia 30909
Mylan Investigator Site Shawnee Mission Kansas 66204
Mylan Investigator Site Paducah Kentucky 42001
Mylan Investigator Site Chevy Chase Maryland 20815
Mylan Investigator Site Ladson South Carolina 29456
Mylan Investigator Site Nashville Tennessee 37203
Mylan Investigator Site Abilene Texas 79606
Mylan Investigator Site Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03610646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2023 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03610646 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →